About Blair Neurologic Associates
Clinical Trials at Blair Neurologic Associates
During the past decade, Blair Neurologic Associates conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 2 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Blair Neurologic Associates
According to Clinical.Site data, the most researched conditions in "Blair Neurologic Associates" are
"Osteoarthritis" (2 trials). Many other conditions were trialed in "Blair Neurologic Associates" in a lesser frequency.
Clinical Trials Intervention Types at Blair Neurologic Associates
Most popular intervention types in "Blair Neurologic Associates" are "Biological" (2 trials) and "Other" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (2 trials), "Tanezumab" (1 trials) and "tanezumab" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Blair Neurologic Associates
The vast majority of trials in "Blair Neurologic Associates" are
2 trials for "All" genders.
Clinical Trials Status at Blair Neurologic Associates
Currently, there are NaN active trials in "Blair Neurologic Associates".
undefined are not yet recruiting,
undefined are recruiting,
undefined are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Blair Neurologic Associates,
undefined suspended trials,
and 2 terminated clinical trials to date.
Out of the total trials that were conducted in Blair Neurologic Associates, 0 "Phase 1"
clinical trials were conducted, 0 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".